Latest Insider Transactions at Crispr Therapeutics Ag (CRSP)
This section provides a real-time view of insider transactions for Crispr Therapeutics Ag (CRSP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CRISPR Therapeutics AG to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CRISPR Therapeutics AG's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 26
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
210,610
-12.18%
|
$10,530,500
$50.12 P/Share
|
|
Apr 26
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
210,610
-12.18%
|
$10,530,500
$50.12 P/Share
|
|
Apr 24
2018
|
Versant Venture Capital V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,841
-1.3%
|
$1,142,050
$50.9 P/Share
|
|
Apr 24
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
22,841
-1.3%
|
$1,142,050
$50.9 P/Share
|
|
Apr 24
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
22,841
-1.3%
|
$1,142,050
$50.9 P/Share
|
|
Apr 23
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
101,994
-5.5%
|
$5,099,700
$50.83 P/Share
|
|
Apr 23
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
101,994
-5.5%
|
$5,099,700
$50.83 P/Share
|
|
Apr 23
2018
|
Versant Venture Capital Iv, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101,994
-5.5%
|
$5,099,700
$50.83 P/Share
|
|
Apr 20
2018
|
Bradley J Ph D Bolzon Director |
BUY
Other acquisition or disposition
|
Direct |
16,262
+26.99%
|
-
|
|
Apr 20
2018
|
Bradley J Ph D Bolzon Director |
SELL
Other acquisition or disposition
|
Indirect |
592,918
-45.44%
|
-
|
|
Apr 20
2018
|
Bradley J Ph D Bolzon Director |
BUY
Other acquisition or disposition
|
Indirect |
92,918
+50.0%
|
-
|
|
Apr 20
2018
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
2,323
+24.19%
|
-
|
|
Apr 20
2018
|
Thomas Woiwode Director |
SELL
Other acquisition or disposition
|
Indirect |
592,918
-45.44%
|
-
|
|
Apr 20
2018
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Indirect |
92,918
+50.0%
|
-
|
|
Apr 20
2018
|
Versant Venture Capital Iv, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
592,918
-45.44%
|
-
|
|
Apr 20
2018
|
Versant Venture Capital Iv, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
92,918
+50.0%
|
-
|
|
Jan 16
2018
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
66,000
-37.48%
|
$1,848,000
$28.11 P/Share
|
|
Jan 16
2018
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+17.33%
|
$252,000
$12.57 P/Share
|
|
Jan 05
2018
|
Aktiengesellschaft Bayer > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
527,472
+8.56%
|
$11,604,384
$22.75 P/Share
|
|
Jan 05
2018
|
Kurt Von Emster Director |
BUY
Open market or private purchase
|
Indirect |
65,934
+3.38%
|
$1,450,548
$22.75 P/Share
|
|
Jan 05
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
92,337
-4.83%
|
$2,400,762
$26.96 P/Share
|
|
Jan 02
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
37,754
-1.93%
|
$981,604
$26.76 P/Share
|
|
Jan 02
2018
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
38,000
-20.08%
|
$874,000
$23.15 P/Share
|
|
Jan 02
2018
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+9.28%
|
$96,000
$12.57 P/Share
|
|
Dec 29
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,300
-6.38%
|
$666,600
$22.49 P/Share
|
|
Dec 29
2017
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,300
+5.84%
|
$198,900
$13.5 P/Share
|
|
Dec 28
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
700
-0.6%
|
$14,700
$21.75 P/Share
|
|
Dec 28
2017
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+0.6%
|
$9,800
$14.43 P/Share
|
|
Dec 22
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
3,059
-38.15%
|
$61,180
$20.29 P/Share
|
|
Dec 22
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
26,016
-48.41%
|
$520,320
$20.3 P/Share
|
|
Dec 22
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-11.52%
|
$300,000
$20.55 P/Share
|
|
Dec 21
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+9.17%
|
$15,000
$1.81 P/Share
|
|
Dec 15
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-10.33%
|
$270,000
$18.9 P/Share
|
|
Dec 04
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,485
-0.81%
|
$579,215
$19.47 P/Share
|
|
Dec 01
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,991
-2.29%
|
$1,671,829
$19.1 P/Share
|
|
Dec 01
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,667
+16.64%
|
$506,673
$19.12 P/Share
|
|
Nov 30
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,666
-0.33%
|
$240,654
$19.04 P/Share
|
|
Nov 29
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,263
-0.11%
|
$80,997
$19.25 P/Share
|
|
Nov 28
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,080
-0.13%
|
$96,520
$19.22 P/Share
|
|
Nov 27
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
27,990
-0.72%
|
$531,810
$19.75 P/Share
|
|
Nov 27
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
200
-0.37%
|
$4,000
$20.24 P/Share
|
|
Nov 27
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
200
-2.43%
|
$4,000
$20.24 P/Share
|
|
Nov 24
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,010
-0.66%
|
$520,200
$20.0 P/Share
|
|
Nov 24
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
1,507
-2.72%
|
$30,140
$20.21 P/Share
|
|
Nov 24
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
1,700
-17.14%
|
$34,000
$20.21 P/Share
|
|
Nov 22
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
256,000
-6.13%
|
$4,864,000
$19.76 P/Share
|
|
Nov 20
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
158,718
-3.6%
|
$3,015,642
$19.02 P/Share
|
|
Nov 17
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,282
-1.15%
|
$923,076
$18.44 P/Share
|
|
Nov 16
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
105,000
-2.3%
|
$1,890,000
$18.39 P/Share
|
|
Nov 15
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.33%
|
$255,000
$17.67 P/Share
|